Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
Regeneron Pharmaceuticals And Sanofi Today Announced That National Medical Products Administration In China Has Approved Dupixent (Dupilumab) As An Add-on Maintenance Treatment For Adults With Uncontrolled Chronic Obstructive Pulmonary Disease
再生元制药公司和赛诺菲安万特今天宣布，中国国家药品监督管理局已批准杜璞珊（Dupilumab）作为一种附加维持治疗，用于治疗患有难以控制的慢性阻塞性肺疾病的成年人。
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life.
在欧盟批准Dupixent用于患有慢性阻塞性肺病且血液中嗜酸性粒细胞升高的成年人之后，该批准是基于两项具有里程碑意义的3期试验，显示Dupixent显著减少了恶化，改善了肺功能，还改善了与健康相关的生活质量。
COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan.
慢性阻塞性肺病是中国最流行的慢性呼吸道疾病，也是政府《健康中国2030》公共卫生计划中的优先事项。
Dupixent is now approved in four indications across respiratory and dermatological diseases in China.
在中国，Dupixent现已获准用于呼吸道和皮肤科疾病的四种适应症。